TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Endometrial Cancer.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase I for Unspecified Neurologic Disorders.

PF-07921585 is under clinical development by Pfizer and currently in Phase I for Metastatic Colorectal Cancer.

Semaglutide biosimilar is under clinical development by Leto Laboratories and currently in Phase II for Diabetes.

ENB-105 is under development for the treatment of inflammatory bowel disease and immune checkpoint inhibitor colitis (ICI-Colitis). It is being developed based on eSTEM systems biology platform.

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.

XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

ND02 is under clinical development by HK inno.N and currently in Phase II for Glaucoma. According to GlobalData, Phase II drugs for Glaucoma have a 39% phase transition success rate (PTSR) indication ...

CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma.